Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warrant...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-12-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6651/7/12/4896 |
| _version_ | 1811187925284552704 |
|---|---|
| author | Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé François Giuliano Pierre Denys |
| author_facet | Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé François Giuliano Pierre Denys |
| author_sort | Amélie Huynh Le Maux |
| collection | DOAJ |
| description | Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. |
| first_indexed | 2024-04-11T14:11:49Z |
| format | Article |
| id | doaj.art-c86ec76a100948eca72695596d50d993 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-04-11T14:11:49Z |
| publishDate | 2015-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-c86ec76a100948eca72695596d50d9932022-12-22T04:19:42ZengMDPI AGToxins2072-66512015-12-017125462547110.3390/toxins7124896toxins7124896Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Amélie Huynh Le Maux0Bernadette Pignol1Delphine Behr-Roussel2Jean-Luc Blachon3Pierre-Etienne Chabrier4Sandrine Compagnie5Philippe Picaut6Jacques Bernabé7François Giuliano8Pierre Denys9Pelvipharm, 2 avenue de la source de la Bièvre, Bâtiment Simone Veil, Université de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, FranceIPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, FrancePelvipharm, 2 avenue de la source de la Bièvre, Bâtiment Simone Veil, Université de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, FranceIPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, FranceIPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, FrancePelvipharm, 2 avenue de la source de la Bièvre, Bâtiment Simone Veil, Université de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, FranceIPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, FrancePelvipharm, 2 avenue de la source de la Bièvre, Bâtiment Simone Veil, Université de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, FranceUnité de Formation et de Recherche des Sciences de la Santé, Université de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Santé Et de la Recherche Médicale U1179, Montigny-le-Bretonneux 78180, FranceUnité de Formation et de Recherche des Sciences de la Santé, Université de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Santé Et de la Recherche Médicale U1179, Montigny-le-Bretonneux 78180, FranceIntradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder.http://www.mdpi.com/2072-6651/7/12/4896abobotulinumtoxinAinjection procedureinjection site numberneurogenic detrusor overactivityspinal-cord injury |
| spellingShingle | Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé François Giuliano Pierre Denys Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins abobotulinumtoxinA injection procedure injection site number neurogenic detrusor overactivity spinal-cord injury |
| title | Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? |
| title_full | Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? |
| title_fullStr | Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? |
| title_full_unstemmed | Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? |
| title_short | Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? |
| title_sort | does reduction of number of intradetrusor injection sites of abobonta dysport r impact efficacy and safety in a rat model of neurogenic detrusor overactivity |
| topic | abobotulinumtoxinA injection procedure injection site number neurogenic detrusor overactivity spinal-cord injury |
| url | http://www.mdpi.com/2072-6651/7/12/4896 |
| work_keys_str_mv | AT ameliehuynhlemaux doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT bernadettepignol doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT delphinebehrroussel doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT jeanlucblachon doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT pierreetiennechabrier doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT sandrinecompagnie doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT philippepicaut doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT jacquesbernabe doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT francoisgiuliano doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity AT pierredenys doesreductionofnumberofintradetrusorinjectionsitesofabobontadysportimpactefficacyandsafetyinaratmodelofneurogenicdetrusoroveractivity |